News

A first patient has been dosed in APOLLOE4, a Phase 3 trial testing the efficacy and safety of ALZ-801, an investigational oral treatment by Alzheon for people carrying a specific genetic variant linked to early onset, rapidly progressive Alzheimer’s disease. ALZ-801 is a small molecule designed to prevent…

The National Institute on Aging (NIA) has awarded a five-year grant worth up to $5 million to support a clinical trial that will test AAV2-BDNF, an investigational gene therapy, in people with Alzheimer’s disease or mild cognitive impairment, which often precedes dementia. The therapy aims to deliver the gene BDNF to…

Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) led to significant improvements in cognition in patients with Alzheimer’s disease, according to data from the first patient group in a Phase 2a study. The improvements were also observed in patients with Parkinson’s disease enrolled in the…

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With this approval, Aduhelm becomes the first disease-modifying therapy for Alzheimer’s, and…

From participating in a fundraiser on the longest day of the year, to sporting purple gear and sharing stories, supporters are marking Alzheimer’s & Brain Awareness Month, as they do each June. The purpose is to raise awareness among the general public, as well as among policymakers, public authorities,…

In a few days, the U.S. Food and Drug Administration (FDA) is expected to announce whether or not it decided that aducanumab, an investigational treatment for Alzheimer’s disease developed by Biogen, merits approval and wide…

ProMIS Neurosciences will advance the development of PMN310, its manmade antibody designed to target the toxic forms of amyloid beta that underlie Alzheimer’s disease. The first step in the manufacturing of PMN310 will be carried out by Selexis with its proprietary CHO-K1 cell line, part of the company’s…

The Alzheimer’s Association and its advocacy affiliate, the Alzheimer’s Impact Movement (AIM), are backing recently introduced bipartisan legislation to support equity in Alzheimer’s disease clinical trials. The Equity in Neuroscience and Alzheimer’s Clinical Trials (ENACT) Act of 2021 (H.R. 3085/S. 1548) would amend the Public Health…

Brown University is establishing the Center for Alzheimer’s Disease Research to build a world-class research program that is focused on the early detection and treatment of Alzheimer’s disease and related disorders. The center is made possible by separate gifts of $25 million and $5 million from donors who wish…

Annovis Bio is seeking orphan drug status for its investigational therapy ANVS401, known as Posiphen, for treating Alzheimer’s disease in people with Down syndrome (DS-AD). The clinical-stage drug platform company has filed an application with the U.S. Food and Drug Administration (FDA) for such designation, granted to therapies for…